Trial Profile
A 12-week Randomized, Patient and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate the Efficacy of LIK066 in Obese Patients With Non-alcoholic Steatohepatitis (NASH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Licogliflozin (Primary)
- Indications Non-alcoholic steatohepatitis; Obesity
- Focus Pharmacodynamics
- Sponsors Novartis; Novartis Pharmaceuticals
- 01 Jul 2022 Primary endpoint (Change From Baseline in Alanine Aminotransferase (ALT) at Week 12) has not been met, according to Results published in the Nature Medicine.
- 01 Jul 2022 Results published in the Nature Medicine
- 11 Feb 2020 Status changed from active, no longer recruiting to completed.